Literature DB >> 28992382

Arterial Inflammation Detected With 18 F-Fluorodeoxyglucose-Positron Emission Tomography in Rheumatoid Arthritis.

Laura Geraldino-Pardilla1, Afshin Zartoshti1, Ayse Bag Ozbek1, Jon T Giles1, Richard Weinberg1, Mona Kinkhabwala1, Sabahat Bokhari1, Joan M Bathon1.   

Abstract

OBJECTIVE: In addition to traditional risk factors, excess cardiovascular disease (CVD) in rheumatoid arthritis (RA) is attributed to enhanced vascular and/or systemic inflammation. In several small studies using 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (18 F-FDG-PET/CT) to directly assess vascular inflammation, FDG uptake was higher in RA patients than in controls. Using a substantially larger sample of RA patients, we sought to identify RA disease characteristics independently associated with vascular FDG uptake.
METHODS: RA patients underwent cardiac FDG-PET/CT, with aortic inflammation assessed by quantification of FDG uptake in the ascending aorta, calculated as the mean and maximum (max) standardized uptake value (SUV) of the entire ascending aorta and of its most diseased segment (SUV MDS). Univariate and multivariable regression models were constructed to model the associations of patient characteristics with aortic FDG uptake.
RESULTS: Ninety-one RA patients were scanned. In multivariable models, in addition to the independent associations of hypertension and body mass index with increased aortic FDG uptake, the prevalence of rheumatoid nodules correlated with the SUV mean and SUV MDS mean measures, while anti-cyclic citrullinated peptide (anti-CCP) antibodies correlated inversely with these measures and with the SUV max and SUV MDS max (P < 0.05). A significant association of RA disease activity with aortic FDG uptake was observed but was restricted to anti-CCP seropositivity.
CONCLUSION: Traditional CV risk factors and RA disease characteristics (rheumatoid nodules and the Disease Activity Score in 28 joints using the C-reactive protein level in anti-CCP antibody-positive individuals) were independently associated with ascending aortic FDG uptake in RA patients without clinical CVD.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28992382      PMCID: PMC5745261          DOI: 10.1002/art.40345

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  45 in total

1.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

2.  Rheumatoid arthritis with rheumatoid heart disease and granulomatous aortitis.

Authors:  K A Reimer; R F Rodgers; R Oyasu
Journal:  JAMA       Date:  1976-06-07       Impact factor: 56.272

3.  The dream of imaging coronary artery inflammation with FDG PET/CT imaging.

Authors:  R Glenn Wells; Terrence D Ruddy
Journal:  J Nucl Cardiol       Date:  2016-06-03       Impact factor: 5.952

4.  Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy.

Authors:  Fleur M van der Valk; Sophie J Bernelot Moens; Simone L Verweij; Aart C Strang; Aart J Nederveen; Hein J Verberne; Michael T Nurmohamed; Dominique L Baeten; Erik S G Stroes
Journal:  Ann Rheum Dis       Date:  2016-04-15       Impact factor: 19.103

5.  Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis.

Authors:  Cynthia S Crowson; Eric L Matteson; Veronique L Roger; Terry M Therneau; Sherine E Gabriel
Journal:  Am J Cardiol       Date:  2012-04-20       Impact factor: 2.778

6.  (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials.

Authors:  James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Ash Rafique; Michael Farkouh; Valentin Fuster; Zahi A Fayad
Journal:  J Am Coll Cardiol       Date:  2007-08-13       Impact factor: 24.094

7.  18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease.

Authors:  Axel Rominger; Tobias Saam; Sarah Wolpers; Clemens C Cyran; Michael Schmidt; Stefan Foerster; Konstantin Nikolaou; Maximilian F Reiser; Peter Bartenstein; Marcus Hacker
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

8.  Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study.

Authors:  James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Mark Woodward; Valentin Fuster; Michael E Farkouh; Zahi A Fayad
Journal:  Circ Cardiovasc Imaging       Date:  2009-01-26       Impact factor: 7.792

9.  Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis.

Authors:  Kaisa M Mäki-Petäjä; Maysoon Elkhawad; Joseph Cheriyan; Francis R Joshi; Andrew J K Ostör; Frances C Hall; James H F Rudd; Ian B Wilkinson
Journal:  Circulation       Date:  2012-10-24       Impact factor: 29.690

10.  Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events.

Authors:  Benoît Paulmier; Michèle Duet; Raphaël Khayat; Nadia Pierquet-Ghazzar; Jean-Pierre Laissy; Christophe Maunoury; Florent Hugonnet; Elisabeth Sauvaget; Ludovic Trinquart; Marc Faraggi
Journal:  J Nucl Cardiol       Date:  2008 Mar-Apr       Impact factor: 3.872

View more
  14 in total

Review 1.  Cardiovascular effects of approved drugs for rheumatoid arthritis.

Authors:  Fabiola Atzeni; Javier Rodríguez-Carrio; Călin D Popa; Michael T Nurmohamed; Gabriella Szűcs; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2021-04-08       Impact factor: 20.543

Review 2.  Novel Surrogate Markers of Cardiovascular Risk in the Setting of Autoimmune Rheumatic Diseases: Current Data and Implications for the Future.

Authors:  Anna Mandel; Andreas Schwarting; Lorenzo Cavagna; Konstantinos Triantafyllias
Journal:  Front Med (Lausanne)       Date:  2022-06-30

Review 3.  2-deoxy-2[18F]fluoro-D-glucose positron emission tomography-computed tomography in rheumatological diseases.

Authors:  Manil Subesinghe; Shaheel Bhuva; Nikita Arumalla; Andrew Cope; David D'Cruz; Sujith Subesinghe
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

Review 4.  PET Scan with Fludeoxyglucose/Computed Tomography in Low-Grade Vascular Inflammation.

Authors:  Aarthi S Reddy; Domingo E Uceda; Mina Al Najafi; Amit K Dey; Nehal N Mehta
Journal:  PET Clin       Date:  2020-04

Review 5.  Application of Non-invasive Imaging in Inflammatory Disease Conditions to Evaluate Subclinical Coronary Artery Disease.

Authors:  Harry Choi; Domingo E Uceda; Amit K Dey; Nehal N Mehta
Journal:  Curr Rheumatol Rep       Date:  2019-12-12       Impact factor: 4.592

6.  Time-Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk.

Authors:  Kazuki Yoshida; Leslie R Harrold; Nicole Middaugh; Hongshu Guan; Scott Stryker; Elaine Karis; Daniel H Solomon
Journal:  ACR Open Rheumatol       Date:  2022-04-10

Review 7.  Mechanisms of vascular comorbidity in autoimmune diseases.

Authors:  György Nagy; Nóra Németh; Edit I Buzás
Journal:  Curr Opin Rheumatol       Date:  2018-03       Impact factor: 5.006

8.  Myocarditis in systemic lupus erythematosus diagnosed by 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Alexandra Perel-Winkler; Sabahat Bokhari; Thania Perez-Recio; Afshin Zartoshti; Anca Askanase; Laura Geraldino-Pardilla
Journal:  Lupus Sci Med       Date:  2018-07-12

Review 9.  Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis.

Authors:  Daniel J DeMizio; Laura B Geraldino-Pardilla
Journal:  Rheumatol Ther       Date:  2019-12-18

Review 10.  Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies.

Authors:  Mir Sohail Fazeli; Vadim Khaychuk; Keith Wittstock; Boris Breznen; Grace Crocket; Mir-Masoud Pourrahmat; Leticia Ferri
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.